Ultralow Dose PET Imaging for Parkinson's Disease and Brain Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical trial is to evaluate an investigational ultralow dose PET imaging technique for Parkinsonian syndromes, neuroendocrine tumors, and gliomas detection and monitoring. The main question it aims to answer is:
Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called 18F-FDOPA and be imaged on a new type of high sensitivity PET scanner for up to 3 hours.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging
Participants are injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours to evaluate image quality and optimize timing and reconstruction.
Follow-up
Participants are monitored for safety and effectiveness after imaging, with data aggregated annually for up to 5 years.
What Are the Treatments Tested in This Trial?
Interventions
- 18F-FDOPA
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Participants will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours
Find a Clinic Near You
Who Is Running the Clinical Trial?
Akiva Mintz
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.